UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 6, 2006
----------------------------
GENELABS TECHNOLOGIES, INC.
- -------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
California 0-19222 94-3010150
- -------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
505 Penobscot Drive, Redwood City, California 94063
- -------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (650) 369-9500
-----------------------------
- -------------------------------------------------------------------------------
(Former name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any of
the following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 OTHER EVENTS.
On January 6, 2006, Genelabs Technologies, Inc. (the "Company") received a
letter from the Nasdaq Stock Market ("Nasdaq") confirming that the Company had
regained compliance with Marketplace Rule 4310(c)(4) (the "Rule") because the
closing bid price of the Company's common stock has been at $1.00 per share or
greater for at least 10 consecutive business days. Nasdaq further advised the
Company that the matter of the Company's compliance with the Rule is now
closed.
A copy of the related press release is filed as Exhibit 99.1 hereto.
Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits
Exhibit Number Description
- -------------- -----------
99.1 Press Release dated January 9, 2006, entitled "Genelabs
Regains Compliance with Nasdaq Capital Market Listing
Requirements"
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
GENELABS TECHNOLOGIES, INC.
By: /s/ Matthew M. Loar
---------------------------
Name: Matthew M. Loar
Title: Chief Financial Officer
Date: January 9, 2006
EXHIBIT INDEX
Exhibit Number Description
- -------------- -----------
99.1 Press Release January 9, 2006, entitled "Genelabs
Regains Compliance with Nasdaq Capital Market Listing
Requirements"